石药集团(01093.HK) 公布,集团开发的I类新药双特异性融合蛋白药物JMT108已获美国食品药品监督管理局(FDA)批准,可在美国开展临床试验。该产品已于3月获中国国家药品监督管理局批准开展临床试验。
JMT108是一 种重组全人源抗PD -1 且融合 IL -15的双 功能融合蛋白,通过靶向PD -1阳性肿瘤浸润免疫细胞等,促进相关免疫细胞的增殖和活化,从而达到增强的抗肿瘤疗效。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-08 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.